Trileptal® (oxcarbazepine) – New contraindication and warning

- On March 23, 2017, the FDA approved new updates to the Trileptal (oxcarbazepine) drug label.

- Trileptal is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults, and as monotherapy in the treatment of partial seizures in pediatric patients aged 4 years and above with epilepsy, and as adjunctive therapy in pediatric patients aged 2 years and above with partial seizures.

- A new update was added to the Contraindications section stating that Trileptal is contraindicated in patients with a known hypersensitivity to Aptiom® (eslicarbazepine).

- The Warnings and Precautions section was updated with new information regarding risk of seizure aggravation.

- Exacerbation of or new onset primary generalized seizures has been reported with Trileptal. The risk of aggravation of primary generalized seizures is seen especially in children but may also occur in adults. In case of seizure aggravation, Trileptal should be discontinued.